Regulatory T cells delay disease progression in Alzheimer-like pathology

Brain

Volumn 139, Issue 4, 2016, Pages 1237-1251

  Dansokho, Cira ^a,b   Ait Ahmed, Dylla ^a,b   Aid, Saba ^a,b   Toly Ndour, Cécile ^a,b   Chaigneau, Thomas ^a,b   Calle, Vanessa ^a,b   Cagnard, Nicolas ^c   Holzenberger, Martin ^a,b   Piaggio, Eliane ^b,d   Aucouturier, Pierre ^a,b   Dorothée, Guillaume ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSERM   (France)

Author keywords

Alzheimer's disease; immunotherapy; microglia; regulatory T cells

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; ALLOGRAFT INFLAMMATORY FACTOR 1; AMYLOID BETA PROTEIN[1-42]; CARBON TETRACHLORIDE; CD4 ANTIGEN; CD68 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; EPHRIN RECEPTOR A5; EPHRIN RECEPTOR A7; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RAB PROTEIN; RAB33A PROTEIN; RAB3B PROTEIN; RAB5A PROTEIN; RAB6 PROTEIN; RECOMBINANT INTERLEUKIN 2; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; INTERLEUKIN 2; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN CORTEX; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION PROFILING; GLIOSIS; GLUCOSE METABOLISM; HIPPOCAMPUS; IMMUNOREACTIVITY; LIPID METABOLISM; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY T LYMPHOCYTE; SPATIAL LEARNING; UPREGULATION; VACCINATION; ANIMAL; BRAIN; C57BL MOUSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MAZE TEST; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-2; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRESENILIN-1; T-LYMPHOCYTES, REGULATORY;

EID: 84962204899     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv408     Document Type: Article

References (46)

1. Baruch K, Deczkowska A, David E, Castellano JM, Miller O, Kertser A, et al. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 2014; 346: 89-93.
2. Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, et al. Breaking immune tolerance by targeting Foxp3( + ) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commu 2015; 6: 7967.
3. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011; 134 (Pt 5): 1293-314.
4. Boraschi D, Tagliabue A. The interleukin-1 receptor family. Semin Immunol 2013; 25: 394-407.
5. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW. Ab-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol Dis 2009; 34: 63-70.
6. Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 2015; 85: 519-33.
7. Duyckaerts C, Potier MC, Delatour B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 2008; 115: 5-38.
8. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B, et al. Ab-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006; 23: 351-61.
9. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14: 11-20.
10. Goldmann T, Zeller N, Raasch J, Kierdorf K, Frenzel K, Ketscher L, et al. USP18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J 2015; 34: 1612-29.
11. Grimaldi LM, Zappala G, Iemolo F, Castellano AE, Ruggieri S, Bruno G, et al. A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects. J Neuroinflammation 2014; 11: 30.
12. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010; 207: 1871-8.
13. Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K, et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 2015; 85: 534-48.
14. Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013; 1: 295-305.
15. Iijima T, Wu K, Witte H, Hanno-Iijima Y, Glatter T, Richard S, et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell 2011; 147: 1601-14.
16. Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system and in Alzheimer's disease. J Mol Cell Biol 2014; 6: 64-74.
17. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-82.
18. Janz R, Sudhof TC, Hammer RE, Unni V, Siegelbaum SA, Bolshakov VY. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 1999; 24: 687-700.
19. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010; 5: e13950.
20. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15: 283-94.
21. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP III, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-66.
22. Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010; 20: 1107-18.
23. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-8.
24. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis 2009; 17: 91-103.
25. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5048-53.
26. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112: 415-22.
27. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5.
28. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331-7.
29. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52.
30. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
31. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014; 10: 217-24.
32. Pilon CB, Petillon S, Naserian S, Martin GH, Badoual C, Lang P, et al. Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice. Am J Transplant 2014; 14: 2874-82.
33. Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675-86.
34. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184: 2261-71.
35. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007; 188: 117-27.
36. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCVinduced vasculitis. N Engl J Med 2011; 365: 2067-77.
37. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-87.
38. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 2014; 158: 15-24.
39. Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Calvo MG, et al. PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2010; 21: 927-38.
40. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
41. Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 2014; 33: 7-22.
42. Shevach EM. Mechanisms of foxp3 + T regulatory cell-mediated suppression. Immunity 2009; 30: 636-45.
43. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 2002; 124: 83-92.
44. Toly-Ndour C, Lui G, Nunes MM, Bruley-Rosset M, Aucouturier P, Dorothee G. MHC-independent genetic factors control the magnitude of CD4 + T cell responses to amyloid-beta peptide in mice through regulatory T cell-mediated inhibition. J Immunol 2011; 187: 4492-500.
45. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008; 14: 681-7.
46. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001; 7: 612-18.